ABSTRACT
Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries, exceeded only by heart disease. The global burden of cancer continues to increase largely because of the aging and growth of the world population along with the increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer in
33.1 Introduction .......................................................................................................................... 393 33.2 Anticancer Pharmacology of Marine Algae ......................................................................... 395
33.2.1 Matrix Metalloproteinase Inhibitors ........................................................................ 396 33.2.2 Nuclear Factor-κB Inhibitors .................................................................................... 396 33.2.3 Hypoxia-Inducible Factor Inhibitors......................................................................... 396 33.2.4 Deoxyribonucleic Acid Methyltransferase-1 Inhibitors ............................................ 397 33.2.5 Deoxyribonucleic Acid Polymerase Inhibitors ......................................................... 397 33.2.6 Teleomerase Inhibitors .............................................................................................. 397 33.2.7 Inosine 5′-Phosphate Dehydrogenase ....................................................................... 397 33.2.8 Apoptosis .................................................................................................................. 398 33.2.9 Antimitotic Agents ................................................................................................... 398 33.2.10 Multidrug Resistance ............................................................................................. 398
33.3 International Scenario........................................................................................................... 399 33.4 Indian Scenario .....................................................................................................................400 33.5 In Silico Methods in Cancer Drug Discovery ......................................................................400 33.6 Conclusion ............................................................................................................................403 References ......................................................................................................................................404
